New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series ...

Digital therapeutics company GAIA has announced the signing of a licensing agreement for attexis with fellow German firm ...

Syncona has launched Slingshot Therapeutics with an initial $15 million investment through its Syncona Accelerator initiative ...

Danish allergy immunotherapy specialist ALK Abello today posted financial results for the third quarter of 2024, which ...

Pharma major Bristol Myers Squibb (NYSE: BMY) and US biotech Cabaletta Bio are set to present promising Phase I data on ...

Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

Apollo Therapeutics and Sunshine Lake Pharma have signed a license deal for APL-18881, a bi-specific fusion protein targeting ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

New York, USA-based rare neurological disease drug developer Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open ...

Lundbeck’s Q3 2024 revenue rose 18% to $815 million, driven by strategic brands like Vyepti and Rexulti in the USA. Vyepti’s ...